pharmaphorum

MARCH 11, 2021

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy for diabetes. . The aim is to replace the pancreatic tissue that is damaged by the autoimmune reaction that underlies type 1 diabetes.

Diabetes 98

Diabetes Immunity Immunization 98

European Pharmaceutical Review

MARCH 8, 2024

Approximately 40 percent of people with type 2 diabetes have chronic kidney disease, so the positive results from FLOW demonstrate the potential for semaglutide to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.”

Diabetes 98

Diabetes Labelling 98

pharmaphorum

SEPTEMBER 17, 2020

Taiwan-based digital health firm Health2Sync has partnered with Sanofi to help patients manage symptoms of diabetes. While Sanofi is winding up its R&D operations in diabetes it is turning to digital solutions to get the most from its established products for the disease. million diabetes patients in Taiwan.

Diabetes 76

Diabetes Hospitals 76

Pharmaceutical Technology

MAY 3, 2024

Despite failing to get an approval for type 1 diabetes in 2019, Lexicon plans to resubmit its NDA to the FDA by mid-2024.

Diabetes 59

Diabetes 59

pharmaphorum

NOVEMBER 30, 2021

Francine Kaufman discusses how Senseonics is helping patients monitor their diabetes with the first fully implantable long-term continuous glucose monitoring (CGM) system. Kaufman has been a practicing pediatric endocrinologist with a focus on diabetes for almost 45 years. She joined the team at Senseonics in 2019.

Diabetes 105

Diabetes 105

pharmaphorum

APRIL 13, 2022

It has now been 100 years since the first patient with diabetes received an injection of insulin, when Leonard Thomas, a 14-year-old boy, was treated with the hormone. In recent years, there have been more developments in the area of diabetes management, with the emergence of metformin and more recently semaglutide and dulaglutide.

Drug Pricing 130

Drug Pricing Diabetes Biosimilars 130

The Guardian - Pharmaceutical Industry

JANUARY 10, 2023

Researchers find overall percentage increase from 0.06% in 2000 to 0.11% in 2019 although safety in children not fully established The proportion of children and young people prescribed antipsychotics in England has nearly doubled in just two decades, prompting concern among some experts. Continue reading.

Diabetes 99

Diabetes 99

Express Pharma

MAY 24, 2024

Innovent Biologics has unveiled Phase III (DREAMS-2) results for mazdutide, indicating superiority over dulaglutide in glycaemic control for type 2 diabetes (T2D) patients in China. Dual agonism at GLP-1R and GCGR could potentially enhance efficacy beyond monotherapies.”

Diabetes 104

Diabetes 104

PharmExec

MARCH 14, 2024

Resubmission plan comes amid feedback and a complete response letter issued by the FDA in 2019 for sotagliflozin in the treatment of glycemic control in type 1 diabetes patients with chronic kidney disease.

Diabetes 52

Diabetes 52

pharmaphorum

DECEMBER 21, 2022

Sosei Heptares’ longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. The post Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2 appeared first on.

Diabetes 52

Diabetes Compounding 52

pharmaphorum

JULY 11, 2022

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The post Vertex buys diabetes cell therapy rival ViaCyte for $320m appeared first on.

Diabetes 59

Diabetes Immunity Immunization 59

Viseven

MARCH 27, 2023

In February 2019, Viseven, a global provider of digital solutions for the life sciences industry, announced a strategic collaboration with a global pharmaceutical company. This company specializes in biopharmaceuticals, diabetes care, obesity care, and other severe chronic diseases. Let us know!

Communication 52

Communication Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 24, 2022

In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease. It was initially developed for type 2 diabetes and was approved for this indication in 2014. The DAPA-HF and DAPA-CKD trials were launched, including patients with and without type 2 diabetes.

Diabetes 119

Diabetes 119

STAT

JULY 10, 2023

were prescribed a GLP-1 agonist in 2022, up from about 230,000 in 2019, according to a recent analysis by data insights company Komodo Health. Around Thanksgiving 2021, Fernandez’s doctor approached him about trying something different: a new weight loss drug called Wegovy.

Communication 246

Communication Diabetes 246

Express Pharma

FEBRUARY 18, 2024

In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD). AstraZeneca progressed tozorakimab into Phase IIb for DKD in 2019, as there was evidence that increased inflammation is associated with deterioration in renal function.

Diabetes 105

Diabetes 105

Express Pharma

AUGUST 23, 2024

Skin and soft tissue infections are the most common type of infections constituting, around 29-32 per cent of all infections in 2018-2019 in India. The treatment of ABSSSI is further complicated by associated comorbidities such as diabetes, obesity, renal and hepatic dysfunction in these patients. The incidence of invasive S.

Diabetes 105

Diabetes 105

pharmaphorum

NOVEMBER 16, 2022

Novartis completed the spin-out of Alcon in 2019, separating products like contact lenses and over-the-counter eyedrops from its prescription eye medicines, headed by age-related macular degeneration (AMD) blockbuster Lucentis (ranibizumab), which is partnered with Roche. billion in the first nine months of this year.

Biosimilars 124

Biosimilars Diabetes 124

pharmaphorum

JULY 29, 2021

The US regulator will review the drug for both neovascular or ‘wet’ age-related macular degeneration (AMD) and diabetic macular oedema (DME), as well as diabetic retinopathy under a standard review. Beovu launched in October 2019 in the US with sales predictions of $2.5

Diabetes 98

Diabetes Biosimilars 98

Drug Channels

JULY 29, 2020

In this issue: Pricing problems for diabetes treatments Controversy over Regeneron’s copay support Massachusetts concedes that coupons help some patients (but accumulators hurt) A 2020 update to my all-time favorite chart Plus, thoughtful perspectives on diversity from AmerisourceBergen CEO Steve Collis.

Diabetes 52

Diabetes Biosimilars 52

pharmaphorum

JULY 27, 2021

Most recently, the French company has secured US and European marketing approvals for a new version of Insulia, a DTx designed for use by people with type 2 diabetes to help them titrate to the correct dose of insulin. Oleena was approved in the US in 2019 and in Europe the following year.

Diabetes 111

Diabetes 111

pharmaphorum

JUNE 24, 2021

Roche bought ex-US rights to the PDS version from Novartis in 2019, giving it total control of the implant product, while Novartis has focused on the development of longer-acting VEGF antibody Beovu (brolucizumab), which is dosed every two or three months. It launched in October 2019 in the US with sales predictions of $2.5

Diabetes 95

Diabetes Biosimilars Drug Development 95

Med Ed 101

DECEMBER 17, 2023

Data from poison control centers across the country indicates a drastic increase over the past year in calls related to semaglutide overdose — an increase of over 1500% since 2019 according to a […] The post Semaglutide Overdose – What Does It Look Like and Why Is It Happening? appeared first on Med Ed 101.

Diabetes 105

Diabetes 105

pharmaphorum

JANUARY 12, 2021

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. Invokana was the first mover among the SGLT2 drugs in the kidney area, winning FDA approval towards the end of 2019 for diabetic kidney disease.

Labelling 76

Labelling Diabetes 76

pharmaphorum

JANUARY 13, 2023

.” He added that people from low-income households and some racial and ethnic groups are disproportionately impacted by the practices, including Hispanic and Black people, who are much more likely to be diagnosed with diabetes than non-Hispanic white people – and much more likely to die as a result of complications.

Diabetes 105

Diabetes Drug Pricing Biosimilars 105

pharmaphorum

JANUARY 6, 2021

Danish drugmaker Novo Nordisk signed a deal with the US biotech in 2019 valued at up to $675.5 million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes.

Diabetes 66

Diabetes Drug Development 66

The Thyroid Pharmacist

SEPTEMBER 2, 2022

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

Diabetes 98

Diabetes Health and Personal Care Stores Immunity Immunization 98

Express Pharma

OCTOBER 16, 2024

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104

Vaccines Immunity Immunization Diabetes 104

The Guardian - Pharmaceutical Industry

JULY 8, 2023

Drug firms are simultaneously funding groups that lobby for greater investment in their disease areas, and in some cases are paying generous consultancy fees to influential ­healthcare professionals, including GPs who have worked as clinical leads for NHS England and have received as much as £480,000 each from industry since 2019.

Diabetes 101

Diabetes 101

pharmaphorum

FEBRUARY 16, 2021

In 2019, Novartis also bought into the category via a $310 million takeover of IFM Therapeutics, which is developing NLRP3 drugs for atherosclerosis and non-alcoholic steatohepatitis (NASH), while UK startup NodThera raised $55 million last year for its own NLRP3 programme, eyeing NASH and diabetes.

Diabetes 119

Diabetes Immunity Immunization 119

pharmaphorum

JULY 13, 2021

Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis. In 2019, for example it agreed to work with Dicerna on gene-silencing for liver-related cardio-metabolic disease in a deal that involved a $225 million upfront payment.

Diabetes 98

Diabetes 98

Pharmaceutical Technology

APRIL 25, 2023

Baqsimi is the first and only nasally given glucagon to treat very low blood sugar, or severe hypoglycaemia, in diabetes patients. Lilly launched the drug in 2019 to provide rescue treatment for diabetes patients who take insulin. It is now available in 27 international markets, with $139.3m in global sales reported last year.

Diabetes 52

Diabetes 52

Pharmaceutical Technology

MARCH 8, 2023

This is the second time Lilly has significantly reduced the cost of its insulin, as in 2019 the company reduced the list price of Humalog by 50%. This recent price reduction to $35 has significant impact as rationing of insulin dosing has led to an increasing number of deaths among diabetics.

Biosimilars 105

Biosimilars Diabetes 105

RX Note

APRIL 10, 2024

Malaysia Medication Adherence Assessment Tool (MyMAAT) The Malaysia Medication Adherence Assessment Tool (MyMAAT) was developed by a multidisciplinary team with expertise in medication adherence and health literacy for use with diabetic patients. External Links Pay up or retract?

Diabetes 52

Diabetes 52

Pharma in Brief

MARCH 1, 2024

The legislation includes a commitment to first launch diabetes medication and contraceptives coverage for Canadians through a universal, single-payer system, contingent on provincial and territorial agreement. Bill C-64 was introduced and had its first reading on February 29, 2024 in the House of Commons.

Diabetes 52

Diabetes 52

RX Note

MAY 31, 2023

Introduction In 2017, the Malaysian Diabetes Educators Society published the Forum for Injection Technique Malaysia (FIT-MY) to provide evidence-based injection technique recommendations for people with diabetes mellitus who use injectable therapy in their daily management. If you have not, repeat steps above.

Diabetes 88

Diabetes Dosage 88

RX Note

JUNE 23, 2023

The common cardiovascular risk factors include: Dyslipidemia Hypertension Diabetes Mellitus Smoking Overweight/obesity Dyslipidemia Dyslipidemia refers to the following lipid levels: Total cholesterol (TC) > 5.2 Patients with established CVD, CKD and diabetes fall into the very high and high risk categories.

Diabetes 52

Diabetes 52

European Pharmaceutical Review

JUNE 28, 2022

According to the World Health Organization (WHO), CVDs are the leading cause of death worldwide accounting for 32 percent of global deaths in 2019 (approximately 17.9 percent of patients with CKD had comorbidities, 11 with a referenced work suggesting diabetes, obesity and hypertension were the most common. Available from: [link].

Diabetes 98

Diabetes 98